NATECH LIMITED
Company number 04510549 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Assessment: Natech Limited (04510549)
Patient profile: A 22-year-old Staffordshire-based chemical manufacturer (SIC 20590), employing 10 people, now part of the Quaker Specialty Chemicals group. Small company regime, audit-exempt, filings fully up to date.
1. Financial Health Score: A− (Strong)
Natech presents as a financially fit patient: a cash-rich, debt-free balance sheet, over two decades of continuous trading, and shareholders' funds that have more than doubled over the past ten years. It is held back from a full "A" by three factors: a small decline in net assets in the latest year, limited visibility of profitability (filleted accounts mean no public P&L), and a recent change of ownership and board that has yet to prove itself in the numbers.
2. Key Vital Signs (Year ended 31 August 2024)
| Vital Sign | Reading | Clinical Interpretation |
|---|---|---|
| Cash & equivalents | £410,133 (+41% YoY) | A strong, steady pulse — the highest cash balance in the company's recorded history |
| Current ratio | 2.96 (£1,149,493 / £388,285) | Excellent — nearly £3 of short-term assets for every £1 of short-term debt (2.0+ is considered robust) |
| Quick ratio | 2.13 | Even stripping out stock, liabilities are covered twice over |
| Cash cover of current liabilities | 1.06× | Cash alone could settle every current liability tomorrow — a rare marker of liquidity health |
| Net current assets (working capital) | £761,208 | A deep working capital reservoir |
| Net assets / Shareholders' funds | £909,988 (−1.5% YoY; +106% since 2015) | Minor blip in an otherwise strong long-term growth trend (~8.4% compound annual growth) |
| Gearing | Nil interest-bearing debt | All liabilities are operational (trade creditors, tax). No borrowings, no lease debt visible — the financial equivalent of clean arteries |
| Equity ratio | 70% of total assets | The business is overwhelmingly funded by its own retained profits, not outsiders' money |
| Fixed assets | £148,780 (incl. £44,000 investments) | Modest, appropriate for a small manufacturer; £26,877 of new plant investment in the year |
3. Symptoms Analysis
The headline symptom — cash up, equity slightly down. Net assets dipped by £13,604 while cash rose by nearly £120,000. This pattern typically indicates one of two things: a small trading loss offset by working capital release, or — more likely given the circumstances — a profitable year from which a dividend was paid to the new parent. The supporting evidence points to the latter: inventories fell 14% (£374k → £321k, releasing cash), trade creditors rose 40% (£174k → £244k), and the tax creditor rose 26% (consistent with taxable profits arising). This looks like cash harvesting under new ownership rather than distress.
The historical cardiac event. In 2018, net assets fell 17% (£109k) and cash nearly halved. The patient made a full recovery — five consecutive years of equity growth followed (2019–2023) — demonstrating genuine resilience, but confirming the business is not immune to shocks.
Ownership transition. The PSC register shows corporate control (Quaker Specialty Chemicals (UK) Ltd / Kolkem Ltd), and the current board consists of Spanish and American directors, while the 2024 accounts were signed by the previous owner-directors (name shown to subscribers and name shown to subscribers). The accounting reference date has also moved from August to December — a classic sign of alignment with a new parent company's reporting calendar. This is a business in post-acquisition transition.
Minor data hygiene note. The PSC register contains duplicate and logically overlapping entries (multiple parties each holding ">75%"), suggesting historic notifications haven't been cleaned up.
4. Diagnosis
A mature, financially sound small manufacturer in rude health, undergoing an ownership transition. The vital organs are strong: the heart (cash generation) is beating powerfully, there is no debt clogging the system, and the equity base (£910k on a £2 share capital — all organically retained profit) provides a substantial cushion against adversity. The 2024 equity dip is a minor symptom, not a disease — most consistent with dividend extraction by a new parent rather than operational decline. The main limitation on this diagnosis is the absence of a published P&L, meaning profitability must be inferred rather than observed directly.
5. Prognosis
Stable to positive. With £410k cash, no borrowings, a decade-long growth record, and the backing of an international chemical group, the company's near-term financial outlook is strong. Key watch-items over the next 24 months: whether margins hold under group ownership, whether dividend policy erodes the equity buffer, and whether the creditor increase is timing-related or the start of supplier-stretching behaviour.
6. Recommendations
- Protect the equity base. Agree a dividend policy with the parent that keeps shareholders' funds above a defined floor, so the balance sheet cushion isn't drained.
- Monitor creditor days. A 40% jump in trade creditors warrants watching — ensure supplier terms aren't being stretched in ways that damage relationships or invite supply risk.
- Maintain capex at or above depreciation. Additions (£27k) ran slightly below the depreciation charge (£32k); sustained under-investment would slowly weaken productive capacity.
- Improve financial transparency. Consider filing fuller accounts (or at least abridged rather than filleted) to support credit ratings, supplier terms, and customer due diligence.
- Tidy the PSC register. Remove or update stale/duplicate entries to present a clean compliance picture to banks, insurers, and counterparties.
- Formalise a cash policy. With cash exceeding total liabilities, define how much is working capital buffer versus surplus available for investment or distribution.